However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

The contraceptive pill may reduce ovarian cancer risk by up to 43% in women over the age of 45, reports a new study.

It’s a little pill with big responsibilities. But despite its primary role to prevent pregnancy, the contraceptive pill (or ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 3061 Mn in 2023, growing at a CAGR of 14.3% ...

Through his work at the Drug Development Unit, Professor Banerji is contributing to the ICR’s efforts to make significant strides in ovarian cancer treatment. His research highlights the importance of ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

ASCO does not endorse third-party drugs, devices, services ... To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Like radiation therapy, certain chemotherapy drugs can also raise risk for a secondary cancer. Chemotherapy for ovarian cancer typically includes a platinum-based drug, such as cisplatin or ...